# US 2010/0303857 A1 · Development of a preventive vaccine for filovirus infection in primates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0303857 A1
- Document ID: US20100303857A1
- Status: Published application
- Kind: A1
- Application number: 12/612,625
- Filed: 2009-11-04
- Published: 2010-12-02
- Earliest claimed: 2001-10-01
- Assignees: Health and Human Services, the Government of the U.S.A. as Represented by the Secretary, Department
- Inventors: Gary J. Nabel; Zhi-yong Yang; Nancy Sullivan; Anthony Sanchez
- Web page: https://patentgrep.com/patent/US20100303857A1

## CPC

- C07K 14/005: from viruses
- A61K 39/12: Viral antigens
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 37/04: Immunostimulants
- A61K 2039/5256: {expressing foreign proteins}
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55522: {Cytokines; Lymphokines; Interferons}
- A61K 2039/70: {Multivalent vaccine}
- C12N 2710/10343: viral genome or elements thereof as genetic vector
- C12N 2760/14122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/14134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/14222: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates generally to viral vaccines and, more specifically, to filovirus vaccines and methods of eliciting an immune response against a filovirus or disease caused by infection with filovirus.

## Claims

### Claim at position 1

1-99. (canceled)

### Claim 100

A vaccine comprising an adenoviral vector comprising a sequence encoding Marburg virus glycoprotein being at least 95% identical to Marburg virus glycoprotein that is encoded in the construct VRC6701 (SEQ ID NO:30).

### Claim 101 (depends on 100)

The vaccine of claim 100, wherein the sequence encoding Marburg virus glycoprotein is the sequence as present in the construct VRC6701 (SEQ ID NO:30).

### Claim 102

A composition for boosting an immune response to a viral antigen in an individual, comprising an adenoviral vector comprising a sequence encoding Marburg virus glycoprotein being at least 95% identical to Marburg virus glycoprotein that is encoded in the construct VRC6701 (SEQ ID NO:30).

### Claim 103 (depends on 102)

The composition of claim 102, wherein the sequence encoding Marburg virus glycoprotein is the sequence as present in construct VRC6701 (SEQ ID NO:30).

### Claim 104

A method for boosting an immune response to a viral antigen in an individual, comprising administering to the individual a composition comprising an adenoviral vector comprising a sequence encoding Marburg virus glycoprotein being at least 95% identical to Marburg virus glycoprotein that is encoded in the construct VRC6701 (SEQ ID NO:30).

### Claim 105 (depends on 104)

The method of claim 104, wherein the sequence encoding Marburg virus glycoprotein is the sequence as present in VRC6701 (SEQ ID NO:30).

### Claim 106 (depends on 104)

The method of claim 104, wherein the viral antigen is a Marburg virus antigen.

### Claim 107 (depends on 104)

The method of claim 104, wherein the administering is performed by injection.

### Claim 108 (depends on 107)

The method of claim 107, wherein the administering is performed at a dose of 5×107 to 1×1012 particles per injection.
